Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: A single center experience

Gynecologic and Obstetric Investigation

Volumn 72, Issue 3, 2011, Pages 208-214

  Chun, Kyoung Chul ^a   Kim, Jae Joon ^b   Kim, Dae Yeon ^b   Kim, Jong Hyeok ^b   Kim, Yong Man ^b   Nam, Joo Hyun ^b   Kim, Young Tak ^b  

^a Inje University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy; Optimal debulking; Ovarian carcinosarcomas; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; OVARIAN CARCINOSARCOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOSARCOMA; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80155153037     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000323775     Document Type: Article

References (27)

1. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M, Awada A: Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007; 17: 316-324. (Pubitemid 46426755)
2. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH: Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006; 16: 101-105.
3. Pfeiffer P, Hardt-Madsen M, Rex S, Holund B, Bertelsen K: Malignant mixed mullerian tumors of the ovary. Report of 13 cases. Acta Obstet Gynecol Scand 1991; 70: 79-83.
4. Barakat RR, Rubin SC, Wong G, Saigo PE, Markman M, Hoskins WJ: Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992; 80: 660-664.
5. Sutton GP, Blessing JA, Homesley HD, Malfetano JH: A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 1994; 53: 24-26.
6. Muntz HG, Jones MA, Goff BA, Fuller AF Jr, Nikrui N, Rice LW, Tarraza HM: Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1995; 76: 1209-1213.
7. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM: Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet Gynecol 1995; 85: 735-739.
8. Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM: A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a gynecologic oncology group study. Gynecol Oncol 1984; 18: 278-292. (Pubitemid 14095027)
9. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, Gore ME: Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995; 6: 755-758.
10. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC: Carcinosarcoma of the ovary. Br J Cancer 2003; 88: 654-657. (Pubitemid 36411438)
11. Terada KY, Johnson TL, Hopkins M, Roberts JA: Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989; 32: 228-232. (Pubitemid 19041967)
12. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004; 100: 2148-2153. (Pubitemid 38580333)
13. Plaxe SC, Dottino PR, Goodman HM, Deligdisch L, Idelson M, Cohen CJ: Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin-and cis-platinum-based chemotherapy. Gynecol Oncol 1990; 37: 244-249. (Pubitemid 20182289)
14. Boucher D, Tetu B: Morphologic prognostic factors of malignant mixed mullerian tumors of the ovary: a clinicopathologic study of 15 cases. Int J Gynecol Pathol 1994; 13: 22-28. (Pubitemid 24006330)
15. Geisler JP, Wiemann MC, Miller GA, Zhou Z, Geisler HE: Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995; 59: 45-47.
16. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS: Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998; 82: 1731-1737. (Pubitemid 28208925)
17. Gallardo A, Matias-Guiu X, Lagarda H, Catasus L, Bussaglia E, Gras E, Suarez D, Prat J: Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases. Int J Gynecol Pathol 2002; 21: 268-272. (Pubitemid 34680344)
18. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E: Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108: 136-140. (Pubitemid 350299436)
19. Baker TR, Piver MS, Caglar H, Piedmonte M: Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991; 14: 246-250.
20. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD: Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a gynecologic oncology group study. Gynecol Oncol 2004; 93: 336-339. (Pubitemid 38507598)
21. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, Mutch DG, Johnson GA, Walker JL, Mannel RS: Carcinosarcoma of the ovary-a case series. Gynecol Oncol 2006; 100: 128-132.
22. Simon SR, Wang SE, Uhl M, Shackney S: Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991; 41: 161-166.
23. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF: Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002; 85: 459-463. (Pubitemid 34651885)
24. Leiser AL, Chi DS, Ishill NM, Tew WP: Carcinosarcoma of the ovary treated with platinum and taxane: the Memorial Sloan-Kettering cancer center experience. Gynecol Oncol 2007; 105: 657-661. (Pubitemid 46734188)
25. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C: A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 2007; 105: 399-403. (Pubitemid 46590332)
26. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP: Chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2000; 79: 196-200.
27. Inthasorn P, Beale P, Dalrymple C, Carter J: Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 2003; 43: 61-64. (Pubitemid 36582531)